Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Randomized, Parallel-Group, 3-Arm, Single-Dose Bioequivalence Study of Bimekizumab Injected Subcutaneously Either by a Prefilled Syringe or by an Auto-Injector in Adult Healthy Participants

NCT03707717 is registered in ClinicalTrials.gov with UCB Biopharma S.P.R.L. as lead sponsor.

NCT NCT03707717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03707717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Randomized, Parallel-Group, 3-Arm, Single-Dose Bioequivalence Study of Bimekizumab Injected Subcutaneously Either by a Prefilled Syringe or by an Auto-Injector in Adult Healthy Participants
Lead sponsor
UCB Biopharma S.P.R.L.
Phase
Phase 1
Overall status
Completed
Start date
October 15, 2018
Completion date
June 5, 2019
Enrollment
189 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers